Reviews Ustekinumab


No reviews yet.

Stelara Injection Drug Description
STELARA™
(ustekinumab) Injection, for Subcutaneous Use
DRUG DESCRIPTION
STELARA™ is a human IgG1α monoclonal antibody against the p40 subunit of the IL-12 and IL-23 cytokines. Using DNA recombinant technology, STELARA™ is produced in a well characterized recombinant cell line and is purified using standard bio-processing technology. The manufacturing process contains steps for the clearance of viruses. STELARA™ is comprised of 1326 amino acids and has an estimated molecular mass that ranges from 148,079 to 149,690 Daltons.
STELARA™ is available as: 45 mg of ustekinumab in 0.5 mL and 90 mg of ustekinumab in 1 mL. STELARA™ is supplied as a sterile solution in a single-use prefilled syringe with a 27 gauge fixed ½ inch needle, or a single-use 2 mL Type I glass vial with a coated stopper. The syringe is fitted with a passive needle guard and a needle cover that is manufactured using a dry natural rubber (a derivative of latex).
Each 45 mg ustekinumab prefilled syringe also contains: L-histidine and L-histidine monohydrochloride monohydrate (0.5 mg), Polysorbate 80 (0.02 mg), and sucrose (38 mg) to fill to a final volume of 0.5 mL.
Each 90 mg ustekinumab prefilled syringe also contains: L-histidine and L-histidine monohydrochloride monohydrate (1 mg), Polysorbate 80 (0.04 mg), and sucrose (76 mg) to fill to a final volume of 1 mL.
Each 45 mg ustekinumab vial also contains: L-histidine and L-histidine monohydrochloride monohydrate (0.5 mg), Polysorbate 80 (0.02 mg), and sucrose (38 mg) to fill to a final volume of 0.5 mL.
Each 90 mg ustekinumab vial also contains: L-histidine and L-histidine monohydrochloride monohydrate (1 mg), Polysorbate 80 (0.04 mg), and sucrose (76 mg) to fill to a final volume of 1 mL.
The STELARA™ solution is colorless to slightly yellow in appearance and has a pH of 5.7-6.3. STELARA™ does not contain preservatives.
Last reviewed on RxList: 2/23/2010




Stelara Injection Drug Description
STELARA™
(ustekinumab) Injection, for Subcutaneous Use
DRUG DESCRIPTION
STELARA™ is a human IgG1α monoclonal antibody against the p40 subunit of the IL-12 and IL-23 cytokines. Using DNA recombinant technology, STELARA™ is produced in a well characterized recombinant cell line and is purified using standard bio-processing technology. The manufacturing process contains steps for the clearance of viruses. STELARA™ is comprised of 1326 amino acids and has an estimated molecular mass that ranges from 148,079 to 149,690 Daltons.
STELARA™ is available as: 45 mg of ustekinumab in 0.5 mL and 90 mg of ustekinumab in 1 mL. STELARA™ is supplied as a sterile solution in a single-use prefilled syringe with a 27 gauge fixed ½ inch needle, or a single-use 2 mL Type I glass vial with a coated stopper. The syringe is fitted with a passive needle guard and a needle cover that is manufactured using a dry natural rubber (a derivative of latex).
Each 45 mg ustekinumab prefilled syringe also contains: L-histidine and L-histidine monohydrochloride monohydrate (0.5 mg), Polysorbate 80 (0.02 mg), and sucrose (38 mg) to fill to a final volume of 0.5 mL.
Each 90 mg ustekinumab prefilled syringe also contains: L-histidine and L-histidine monohydrochloride monohydrate (1 mg), Polysorbate 80 (0.04 mg), and sucrose (76 mg) to fill to a final volume of 1 mL.
Each 45 mg ustekinumab vial also contains: L-histidine and L-histidine monohydrochloride monohydrate (0.5 mg), Polysorbate 80 (0.02 mg), and sucrose (38 mg) to fill to a final volume of 0.5 mL.
Each 90 mg ustekinumab vial also contains: L-histidine and L-histidine monohydrochloride monohydrate (1 mg), Polysorbate 80 (0.04 mg), and sucrose (76 mg) to fill to a final volume of 1 mL.
The STELARA™ solution is colorless to slightly yellow in appearance and has a pH of 5.7-6.3. STELARA™ does not contain preservatives.
Last reviewed on RxList: 2/23/2010




Stelara Injection Drug Description
STELARA™
(ustekinumab) Injection, for Subcutaneous Use
DRUG DESCRIPTION
STELARA™ is a human IgG1α monoclonal antibody against the p40 subunit of the IL-12 and IL-23 cytokines. Using DNA recombinant technology, STELARA™ is produced in a well characterized recombinant cell line and is purified using standard bio-processing technology. The manufacturing process contains steps for the clearance of viruses. STELARA™ is comprised of 1326 amino acids and has an estimated molecular mass that ranges from 148,079 to 149,690 Daltons.
STELARA™ is available as: 45 mg of ustekinumab in 0.5 mL and 90 mg of ustekinumab in 1 mL. STELARA™ is supplied as a sterile solution in a single-use prefilled syringe with a 27 gauge fixed ½ inch needle, or a single-use 2 mL Type I glass vial with a coated stopper. The syringe is fitted with a passive needle guard and a needle cover that is manufactured using a dry natural rubber (a derivative of latex).
Each 45 mg ustekinumab prefilled syringe also contains: L-histidine and L-histidine monohydrochloride monohydrate (0.5 mg), Polysorbate 80 (0.02 mg), and sucrose (38 mg) to fill to a final volume of 0.5 mL.
Each 90 mg ustekinumab prefilled syringe also contains: L-histidine and L-histidine monohydrochloride monohydrate (1 mg), Polysorbate 80 (0.04 mg), and sucrose (76 mg) to fill to a final volume of 1 mL.
Each 45 mg ustekinumab vial also contains: L-histidine and L-histidine monohydrochloride monohydrate (0.5 mg), Polysorbate 80 (0.02 mg), and sucrose (38 mg) to fill to a final volume of 0.5 mL.
Each 90 mg ustekinumab vial also contains: L-histidine and L-histidine monohydrochloride monohydrate (1 mg), Polysorbate 80 (0.04 mg), and sucrose (76 mg) to fill to a final volume of 1 mL.
The STELARA™ solution is colorless to slightly yellow in appearance and has a pH of 5.7-6.3. STELARA™ does not contain preservatives.
Last reviewed on RxList: 2/23/2010




Stelara Injection Drug Description
STELARA™
(ustekinumab) Injection, for Subcutaneous Use
DRUG DESCRIPTION
STELARA™ is a human IgG1α monoclonal antibody against the p40 subunit of the IL-12 and IL-23 cytokines. Using DNA recombinant technology, STELARA™ is produced in a well characterized recombinant cell line and is purified using standard bio-processing technology. The manufacturing process contains steps for the clearance of viruses. STELARA™ is comprised of 1326 amino acids and has an estimated molecular mass that ranges from 148,079 to 149,690 Daltons.
STELARA™ is available as: 45 mg of ustekinumab in 0.5 mL and 90 mg of ustekinumab in 1 mL. STELARA™ is supplied as a sterile solution in a single-use prefilled syringe with a 27 gauge fixed ½ inch needle, or a single-use 2 mL Type I glass vial with a coated stopper. The syringe is fitted with a passive needle guard and a needle cover that is manufactured using a dry natural rubber (a derivative of latex).
Each 45 mg ustekinumab prefilled syringe also contains: L-histidine and L-histidine monohydrochloride monohydrate (0.5 mg), Polysorbate 80 (0.02 mg), and sucrose (38 mg) to fill to a final volume of 0.5 mL.
Each 90 mg ustekinumab prefilled syringe also contains: L-histidine and L-histidine monohydrochloride monohydrate (1 mg), Polysorbate 80 (0.04 mg), and sucrose (76 mg) to fill to a final volume of 1 mL.
Each 45 mg ustekinumab vial also contains: L-histidine and L-histidine monohydrochloride monohydrate (0.5 mg), Polysorbate 80 (0.02 mg), and sucrose (38 mg) to fill to a final volume of 0.5 mL.
Each 90 mg ustekinumab vial also contains: L-histidine and L-histidine monohydrochloride monohydrate (1 mg), Polysorbate 80 (0.04 mg), and sucrose (76 mg) to fill to a final volume of 1 mL.
The STELARA™ solution is colorless to slightly yellow in appearance and has a pH of 5.7-6.3. STELARA™ does not contain preservatives.
Last reviewed on RxList: 2/23/2010




Stelara Injection Drug Description
STELARA™
(ustekinumab) Injection, for Subcutaneous Use
DRUG DESCRIPTION
STELARA™ is a human IgG1α monoclonal antibody against the p40 subunit of the IL-12 and IL-23 cytokines. Using DNA recombinant technology, STELARA™ is produced in a well characterized recombinant cell line and is purified using standard bio-processing technology. The manufacturing process contains steps for the clearance of viruses. STELARA™ is comprised of 1326 amino acids and has an estimated molecular mass that ranges from 148,079 to 149,690 Daltons.
STELARA™ is available as: 45 mg of ustekinumab in 0.5 mL and 90 mg of ustekinumab in 1 mL. STELARA™ is supplied as a sterile solution in a single-use prefilled syringe with a 27 gauge fixed ½ inch needle, or a single-use 2 mL Type I glass vial with a coated stopper. The syringe is fitted with a passive needle guard and a needle cover that is manufactured using a dry natural rubber (a derivative of latex).
Each 45 mg ustekinumab prefilled syringe also contains: L-histidine and L-histidine monohydrochloride monohydrate (0.5 mg), Polysorbate 80 (0.02 mg), and sucrose (38 mg) to fill to a final volume of 0.5 mL.
Each 90 mg ustekinumab prefilled syringe also contains: L-histidine and L-histidine monohydrochloride monohydrate (1 mg), Polysorbate 80 (0.04 mg), and sucrose (76 mg) to fill to a final volume of 1 mL.
Each 45 mg ustekinumab vial also contains: L-histidine and L-histidine monohydrochloride monohydrate (0.5 mg), Polysorbate 80 (0.02 mg), and sucrose (38 mg) to fill to a final volume of 0.5 mL.
Each 90 mg ustekinumab vial also contains: L-histidine and L-histidine monohydrochloride monohydrate (1 mg), Polysorbate 80 (0.04 mg), and sucrose (76 mg) to fill to a final volume of 1 mL.
The STELARA™ solution is colorless to slightly yellow in appearance and has a pH of 5.7-6.3. STELARA™ does not contain preservatives.
Last reviewed on RxList: 2/23/2010





Other reviews about Ustekinumab on wordpress

New Biologic Ustekinumab Receives Positive Opinion From European Regulatory Authority For The Treatment Of Moderate To Severe Plaque Psoriasis
  by Remit2India
Janssen-Cilag announced that ustekinumab, the first in a new class of biologics, has received a positive opinion for the treatment of adults with moderate to severe plaque psoriasis […]


New Biologic STELARA(TM) Receives Approval In Europe For Treatment Of Moderate To Severe Plaque Psoriasis
  by yestelli
Janssen-Cilag announced that STELARA(TM) (ustekinumab), the first in a new class of biologics, has been approved by the European Commission for use across Europe. The approved indication of […]


Ustekinumab In The Treatment Of Psoriatic Arthritis: Investigational Study Published
  by enartion
A group of patients suffering from potentially debilitating psoriatic arthritis showed significant and prolonged improvement after treatment with ustekinumab, according to data from a randomized, double-blind, placebo-controlled study […]


Drug Reduces Inflammatory Arthritis Symptoms, Lesions
  by timeinctemp
THURSDAY, Feb. 12 (HealthDay News) — The drug ustekinumab shows promise against psoriatic arthritis (PA), according to a study that included patients from 24 sites in Europe and […]


New Biologic Ustekinumab Receives Positive Opinion From European Regulatory Authority For The Treatment Of Moderate To Severe Plaque Psoriasis
  by saludmasculinanoticias
JanssenCilag announced that ustekinumab, the first in a new class of biologics, has received a positive opinion for the treatment of adults with moderate to […]


Ustekinumab In The Treatment Of Psoriatic Arthritis: Investigational Study Published
  by maciekmaciek5
A group of patients suffering from potentially debilitating psoriatic arthritis showed significant and prolonged improvement after treatment with ustekinumab, according to data from a randomized, double-blind, placebo-controlled study […]


Newer Drug More Effective in Psoriasis Treatment
  by timeinctemp
WEDNESDAY, Jan. 13 (HealthDay News) — The estimated 7.5 million Americans suffering from psoriasis often have to tolerate long-term treatment that may be only moderately effective. Now, a new […]


Biologics
  by Dr. Mark
Biologics (also called “disease-modifying therapy” or “immunomodulators”) are a relatively new treatment option for people with moderate to severe psoriasis. They are given this name because they are […]


Stelara (ustekinumab) improves depression and anxiety.
  by Dr. Mark
[caption id="" align="alignleft" width="137" caption="Study Author, Dermatologist, Steve Feldman, M.D."][/caption] Stelara (ustekinumab), one of the newer biologic medications prescribed for the treatment of psoriasis was found to reduce mild-to-severe […]



Other reviews about Ustekinumab on web:

Ustekinumab (INN, experimental name CNTO 1275, proprietary commercial name Stelara Centocor) is a human monoclonal antibody. It is directed against interleukin 12 and interleukin 23 ... Ustekinumab - Wikipedia, the free encyclopedia


Ustekinumab Treatment for Plaque Psoriasis ... Ustekinumab (CNTO 1275), a human anti-interleukin 12 (IL-12) and anti-interleukin 23 (IL-23) monoclonal antibody (MAb), is a ... Ustekinumab, Treatment for Plaque Psoriasis by Centocor and ...


Ustekinumab is a new drug in development for the treatment of moderate to severe plaque psoriasis. Ustekinumab information includes news, clinical trial results and side effects. FDA Issues Complete Response Letter to Centocor for Ustekinumab ...


Centocor, Inc. announced that the Biologics License Application (BLA) for ustekinumab (CNTO 1275) has been accepted for review by the U.S. Food and Drug Administration (FDA) for ... Centocor Announces Ustekinumab Biologic License Application ...


Learn more about Ustekinumab. Find the Web's best health guides, medical reports, news, videos and tools for Ustekinumab. Share Ustekinumab experiences and get advice from experts. Ustekinumab Overview - References, Advice, News, Videos, Coping ...


A group of patients suffering from potentially debilitating psoriatic arthritis showed significant and prolonged improvement after treatment with ustekinumab, according to data ... Psoriatic Arthritis Treatment of Ustekinumab Effective, Study Suggests


Ustekinumab information from Drugs.com, includes Ustekinumab side effects, interactions and indications. Centocor and Janssen-Cilag Submit Applications Requesting Approval ...


Ustekinumab (Stelara) is a drug prescribed for the treatment of plaque psoriasis in adults. Side effects, drug interactions, and dosing information is included. Ustekinumab (Stelara) Drug Information by MedicineNet.com


Ustekinumab (Stelara®) is a novel human monoclonal antibody that specifically targets the cytokines interleukin 12 (IL-12) and interleukin 23 (IL-23). Interleukins are naturally ... Ustekinumab (Stelara®)


A Study of Safety and Effectiveness of Ustekinumab in Patients With Moderate to Severe Active Crohns Disease Who Have Been Previously Treated With Anti-TNF Therapy A Study of Safety and Effectiveness of Ustekinumab in Patients ...





Featured Reviews

Reviews Misoprostol

Cytotec Drug Description Cytotec® (misoprostol) Tablets WARNINGS CYTOTEC (MISOPROSTOL) ADMINISTRATION TO WOMEN WHO ARE PREGNANT CAN CAUSE ABORTION, PREMATURE BIRTH, OR BIRTH DEFECTS. UTERINE RUPTURE HAS BEEN REPORTED WHEN...
Read More  |  Review This
Reviews Intron A - Rebetol

Intron A - Rebetol Drug Description DRUG DESCRIPTION REBETOL ® REBETOL is Schering Corporations brand name for ribavirin, a nucleoside analog with antiviral activity. The chemical name of ribavirin is 1-J-D-ribofuranosyl-1H-1,2,4-triazole-3-...
Read More  |  Review This
Reviews Methylphenidate Hydrochloride Extended-Release Capsules

Ritalin LA Drug Description Ritalin LA® (methylphenidate hydrochloride) Extended-Release Capsules DRUG DESCRIPTION What are the possible side effects of methylphenidate? Get emergency medical help if you have any of these...
Read More  |  Review This
Reviews Methadone Hydrochloride Tablets

Methadone Hydrochloride Drug Description METHADONE HYDROCHLORIDE TABLETS USP 5 mg, 10 mg Deaths, cardiac and respiratory, have been reported during initiation and conversion of pain patients to methadone treatment from treatment...
Read More  |  Review This
Reviews Duetact

Duetact Drug Description DUETACT® (pioglitazone hydrochloride and glimepiride) Tablets WARNING CONGESTIVE HEART FAILURE Thiazolidinediones, including pioglitazone, which is a component of DUETACT, cause or exacerbate congestive...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....